Who
Gary J. Nabel
Director
Company insider
Files Form 4 as: Director, Candel Therapeutics; Director, SIGA Technologies; Chief Innovation Officer, Opko Health.
In numbers
- Trades disclosed
- 65
- Buys
- 5
- Sells
- 0
- Bought
- $1.9M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 15 Jun 2021
- Last trade
- 23 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code M | —24,116 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code D | $32K7,235 at $4.39 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,116 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,116 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —34,169 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —34,169 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code M | —24,116 | filing |
| 9 Jun 2026filed 10 Jun 2026 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code D | $32K7,235 at $4.39 | filing |
| 25 Jun 2025filed 26 Jun 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | $25K5,353 at $4.67 | filing |
| 17 Jun 2025filed 18 Jun 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,240 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,084 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —24,116 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code M | —19,084 | filing |
| 10 Jun 2025filed 11 Jun 2025 | SIGA SIGA TechnologiesPharmaceuticals | SEC FORM 4 Code D | $36K5,725 at $6.22 | filing |
| 27 May 2025filed 29 May 2025 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —437,500 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OPK Opko HealthBiotechnology | SEC FORM 4 Code A | —437,500 at $0.00 | filing |
| 26 Jun 2024filed 27 Jun 2024 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,240 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | SIGA SIGA Technologiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,712 at $0.00 | filing |
News
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthOPK · prnewswire.com · 15 Oct 2026
0 headlines in the last 90 days name Gary J. Nabel; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.